We have reported that the sequence variation in the tenomodulin (TNMD) gene is associated with the risk of type 2 diabetes (T2DM), central obesity and serum levels of systemic immune mediators in the Finnish Diabetes Prevention Study (DPS), which is a longitudinal lifestyle intervention study on 522 middle-aged persons with impaired glucose tolerance (IGT). The aim of this study was to investigate whether the association with T2DM, observed in the DPS could be replicated in a larger, cross-sectional population-based random sample of 5298 men (3020 with normoglycaemia, 984 with impaired fasting glucose, 436 with IGT and 811 with T2DM) from the region of Kuopio, eastern Finland. To further explore the putative mechanisms linking TNMD to T2DM and metabolic syndrome, we studied the associations of TNMD sequence variation with lipid abnormalities characteristic to metabolic syndrome. The association with T2DM risk was not replicated, but significant associations were found with serum low-density lipoprotein and total cholesterol in a body mass index-dependent manner. These associations were also observed in the men of DPS, whereas in women these associations were not significant. These results from two independent study populations suggest that the genetic variation in TNMD could modulate cholesterol metabolism in obese men.
Introduction
We have previously reported that single-nucleotide polymorphisms of the tenomodulin gene (TNMD) are associated with parameters of central obesity in women and with impaired glucose tolerance (IGT) metabolism and its conversion to type 2 diabetes (T2DM) in men 1 and with serum levels of systemic immune mediators in both genders. 2 The TNMD gene is located in the X chromosome and the transcript levels are approximately two times higher in women than in men. 3 This observation might suggest that TNMD escapes X-inactivation. TNMD is an integral transmembrane protein belonging to the BRICHOS family, whose members are associated with chronic diseases caused by misfolded proteins. 4 The C-terminal domain of TNMD, which inhibits angiogenesis, 5 is cleaved from a larger precursor so that the BRICHOS domain remains in the propeptide region and functions as an intramolecular chaperone for the secreted part. 4, 6 The transmembrane form of TNMD is present in the skeletal muscle and ocular tissues, 7 whereas the cleaved secreted form has been detected in the tail tendon. 6 TNMD has been mainly studied in the context of hypovascular connective tissues, 5, 6 but also weight reduction has been shown to downregulate the expression of TNMD in adipose tissue. 3, 8 Furthermore, we have recently
shown that the downregulation of TNMD because of weight reduction correlates with the improvement of insulin sensitivity in patients with features of metabolic syndrome. 3 As the associations reported earlier of sequence variation in TNMD with T2DM risk in the Finnish Diabetes Prevention Study (DPS) were based on a relatively small number of cases (115/507), our purpose was to investigate whether these results could be replicated in a larger cross-sectional study. On account of the associations observed earlier between TNMD single-nucleotide polymorphisms and features of the metabolic syndrome, we also studied the associations of TNMD sequence variation with lipid abnormalities by examining associations with serum trigylcerides and total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and whether these associations were modified by body size.
Materials and methods

The Metabolic Syndrome in Men Study
The Metabolic Syndrome in Men (METSIM) study population is a random population-based sample of 5298 Finnish 50-to 70-year-old men living in the city of Kuopio in eastern Finland. 9 The diagnosis of T2DM was performed according to the WHO's 1999 criteria. 10 The methodology for serum measurements has been described elsewhere. 9 From the patients of this study, 3020 were normoglycaemic, 984 had impaired fasting glucose, 436 had IGT and 811 had known or newly diagnosed diabetes. The study was in accordance with the standards of the Helsinki Declaration. The Ethics Committee of the District Hospital Region of Northern Savo and Kuopio University Hospital approved the study plan. All participants gave their written informed consent.
The Finnish Diabetes Prevention Study
The Finnish Diabetes Prevention Study is a randomized, controlled, multicenter lifestyle intervention study conducted in Finland. In the current study only the baseline data of serum lipoproteins was analysed. Study design and methodology have been reported elsewhere in detail. 11, 12 The main inclusion criteria were body mass index (BMI) over 25 kg/m 2 , age 40-64 years and IGT on the basis of the mean values of two oral glucose tolerance tests. DNA was available from 507 individuals (166 men and 341 women). The study protocol was approved by the Ethics Committee of the National Public Health Institute in Helsinki, Finland and the participants gave written informed consent. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
Single-nucleotide polymorphism rs2073162 that had a modest association with T2DM risk in men of the DPS 1 was genotyped in the METSIM study with TaqMan Allelic Discrimination Assay according to the manufacturer's instructions using ABI PRISM 7000 sequence detector (Applied Biosystems, Foster City, CA, USA). Markers rs2073162, rs2073163 and rs1155974 that were associated with T2DM risk in our previous study were genotyped from 2045 participants of the METSIM study, but as the three markers were in complete linkage disequilibrium, genotyping was continued only for rs2073162. The error rate for genotyping was estimated by repeating a random sample of 3.5% of the METSIM study population and 6.3% of the DPS population. 
Results
The association with the risk of T2DM observed in the DPS was not replicated in the METSIM study ( Table 1 ). The marker rs2073162 was not associated with body size or parameters of glucose metabolism (Table 1) . Genetic associations with the serum lipids and lipoproteins were not observed in the METSIM study (Table 1) , but genotype*BMI interactions were observed (Po0.0005 for interaction between rs2073162 and BMI as a categorical variable regarding all serum lipoproteins and lipids). However, when BMI was modelled as continuous variable, the interaction was significant only for serum HDL, LDL and triglycerides (Pp0.001 for each, P ¼ 0.501 for serum total cholesterol).
In further analyses according to the quartiles of BMI no associations were found in the three lowest quartiles, but in the highest quartile the carriers of the rs2073162-A-allele had higher concentrations of total serum cholesterol (P ¼ 0.009), LDL (P ¼ 0.027) and HDL (P ¼ 0.025, all adjusted for BMI, Figure 1 ) than carriers of the rs2073162-G-allele, whereas no difference was observed with the serum triglyceride levels. The differences remained statistically signi- ), respectively. In the DPS no differences were observed in either gender when all individuals were included in the analysis (Table 1) , but as in the METSIM study, BMI*rs2073162 interactions were observed (Po0.05 for LDL and HDL cholesterol, P ¼ 0.08 for serum triglycerides and P ¼ 0.187 for serum total cholesterol). When BMI was modelled as continuous variable, the corresponding P-values were 0.220, 0.062, 0.002 and 0.747. In the data stratified by the median of BMI, the genotype was not associated with the serum lipoproteins or lipids in either median in women or in the lower median in men. In the upper median in men, associations with serum total cholesterol and LDL were observed (P ¼ 0.032, 0.011, respectively, adjusted for the use of cholesterol-lowering medication) (Figure 2 
Discussion
According to our results the rs2073162 of TNMD was associated with serum lipoproteins in a BMI-dependent manner in two independent studies including Finnish men. In the METSIM study, the differences in total, HDL and LDL cholesterol were observed, whereas in the DPS the differences were found only in total and LDL cholesterol levels. These results are in line with our earlier findings, as the rs2073162-A allele was also associated with modestly TNMD is associated with serum lipoproteins A-M Tolppanen et al elevated risk for developing T2DM and with elevated serum levels of acute phase reactants in the DPS.
1,2
The METSIM and DPS study populations are essentially different: both men and women were included in the DPS and the sample was collected from five Finnish cities and surroundings. The patients were also relatively homogeneous, as all of the study participants had BMI425 kg/m 2 and IGT. The METSIM study population is a random sample of men aged from 45 to 70 years and living in Kuopio area. Therefore, the range for BMI is considerably larger (16.18-52.11 kg/m 2 ) and all glucose tolerance categories were included. Furthermore, in the METSIM study the, prevalence of T2DM was determined, whereas in the DPS study the conversion of IGT to T2DM was assessed. These differences might explain why the association with T2DM could not be replicated.
Despite the differences, the associations between rs2073162 of TNMD and serum lipoproteins were observed in both study populations among individuals who had higher BMI. The connection between obesity and serum lipid and lipoprotein levels has been established in large epidemiological and clinical studies and further demonstrated by the relation of weight change to alterations in serum lipoproteins. 13 Hepatic overproduction of lipoproteins containing apoB-100 14 and excessive intake of saturated fatty acids and cholesterol 15 have been proposed to account for higher total and LDL-cholesterol concentrations among obese individuals. Furthermore, the increased cholesterol synthesis is known to partially account for the elevated serum total cholestrol levels in obese individuals. 16 As the indicators of metabolism were not measured in either study, we cannot postulate whether these differences result from increased cholesterol synthesis, differences in its absorption or disturbances of catabolism of cholesterol-rich lipoproteins. In our previous study, we observed that the marker rs2073162 was associated with serum concentrations of acute phase reactants serum amyloid A and C-reactive protein in the DPS. 2 Both serum amyloid A and C-reactive protein reflect inflammatory status and have shown to be involved in cholesterol recycling. 17 Thus, the associations of TNMD with inflammatory status could explain these associations with serum lipoproteins. TNMD is expressed in adipose tissue, 3, 8 and according to Gene Atlas database 18 (http://symatlas.gnf.org/SymAtlas/), TNMD expression is detected specifically in adipocytes, albeit in a modest level. Our preliminary data also support this finding. It is possible that the secreted form of TNMD is released from the adipose tissue to remote organs. Alternatively, TNMD produced in the sites other than the adipose tissue might be involved in regulation of cholesterol metabolism in obese men or TNMD could affect lipid biosynthesis in adipose tissue. However, further studies are needed to elucidate the mechanisms of these associations. The observed gender differences can arise from the genetic locus. X-chromosomal genes show significant variation in expression and function between men and women, partially because of variation in gene dosages and random inactivation of one of the X-chromosomes in women. 19 It seems that TNMD locus escapes the inactivation, indicated by dosagespecific expression levels. 3 Furthermore, the cellular microenvironment can differ by gender because of differences in hormone levels and gene expression. 20 The monosomy of X-chromosome is related to serum lipid profile, specifically the 45, X women generally have higher LDL-cholesterol and triglyceride levels and smaller LDL and HDL particle size than women with 46, XX. 21 The degree of differences in lipid levels and particle size were similar to the genderwise differences. 22 Genomic imprinting of X-linked genes can also lead into different gene expression between genders, as women are normally mosaic for maternally and paternally inherited active X-chromosomes, whereas men are monosomic for the maternally inherited X-chromosome and therefore express only the maternally inherited genes in that locus. 23 Accordingly, among women with Turner's syndrome (45,X), those with maternally inherited X-chromosome have greater visceral fat accumulation and more atherogenic lipid profile than women with paternally inherited X-chromosome. 23 These observations make X-chromosome an interesting locus for candidate genes for lipid-related traits. TNMD is associated with serum lipoproteins A-M Tolppanen et al
